These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16230677)

  • 21. Efficacy and feasibility of cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma.
    Demizu Y; Sasaki R; Soejima T; Maruta T; Okamoto Y; Yamada K; Yoden E; Ejima Y; Ota Y; Ishida H; Nibu K; Sugimura K
    Jpn J Clin Oncol; 2006 Oct; 36(10):620-5. PubMed ID: 16905756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
    Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a prospective randomised trial comparing conventional radiotherapy to split course bifractionated radiation therapy in patients with nasopharyngeal carcinoma.
    Daoud J; Toumi N; Siala W; Ghorbel A; Drira MM; Frikha M
    Radiother Oncol; 2007 Oct; 85(1):17-23. PubMed ID: 17343938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis.
    Lin YS; Lin LC; Lin SW
    Laryngoscope; 2009 Jul; 119(7):1348-52. PubMed ID: 19402154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma.
    Lee AW; Tung SY; Chan AT; Chappell R; Fu YT; Lu TX; Tan T; Chua DT; O'sullivan B; Xu SL; Pang ES; Sze WM; Leung TW; Kwan WH; Chan PT; Liu XF; Tan EH; Sham JS; Siu L; Lau WH
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):142-51. PubMed ID: 16904519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial.
    Chan AT; Teo PM; Ngan RK; Leung TW; Lau WH; Zee B; Leung SF; Cheung FY; Yeo W; Yiu HH; Yu KH; Chiu KW; Chan DT; Mok T; Yuen KT; Mo F; Lai M; Kwan WH; Choi P; Johnson PJ
    J Clin Oncol; 2002 Apr; 20(8):2038-44. PubMed ID: 11956263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
    Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
    Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia.
    Lu H; Peng L; Yuan X; Hao Y; Lu Z; Chen J; Cheng J; Deng S; Gu J; Pang Q; Qin J
    Cancer Treat Rev; 2009 Jun; 35(4):345-53. PubMed ID: 19211192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.
    Lin JC; Jan JS; Hsu CY; Liang WM; Jiang RS; Wang WY
    J Clin Oncol; 2003 Feb; 21(4):631-7. PubMed ID: 12586799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity and feasibility analysis for cisplatin-based concomitant chemoradiotherapy in locally advanced nasopharyngeal carcinoma.
    Atasoy BM; Dane F; Yumuk PF; Akgün Z; Turhal NS; Abacioğlu U; Sengöz M
    J BUON; 2008; 13(1):43-50. PubMed ID: 18404785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of hemoglobin levels on treatment outcome in patients with nasopharyngeal carcinoma treated with sequential chemoradiotherapy or radiotherapy alone.
    Chua DT; Sham JS; Choy DT
    Cancer; 2004 Jul; 101(2):307-16. PubMed ID: 15241828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series.
    Lin S; Pan J; Han L; Zhang X; Liao X; Lu JJ
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1071-8. PubMed ID: 19362784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined-modality treatment for advanced oral tongue squamous cell carcinoma.
    Fan KH; Lin CY; Kang CJ; Huang SF; Wang HM; Chen EY; Chen IH; Liao CT; Cheng AJ; Chang JT
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):453-61. PubMed ID: 17236967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for recurrence and survival rate.
    Chu ST; Wu PH; Chou P; Lee CC
    Eur Arch Otorhinolaryngol; 2008 Jul; 265 Suppl 1():S115-20. PubMed ID: 18236065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent chemoradiotherapy with nedaplatin after radical hysterectomy in patients with stage IB and II cervical cancer.
    Kobayashi Y; Ohara T; Wada Y; Okuda Y; Kondo H; Okuma Y; Suzuki N; Gomi H; Kiguchi K; Ishizuka B
    J Obstet Gynaecol Res; 2009 Jun; 35(3):490-4. PubMed ID: 19527388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Kim K; Wu HG; Kim HJ; Sung MW; Kim KH; Lee SH; Heo DS; Kim HJ; Park CI
    Head Neck; 2009 Sep; 31(9):1121-8. PubMed ID: 19340863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes.
    Xu T; Zhu G; He X; Ying H; Hu C
    Oral Oncol; 2014 Feb; 50(2):71-6. PubMed ID: 24315404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.